Gastric cancer cases with focal gene amplification of HER2 and FGFR2 in different parts of the tumor tissue have been reported [39, 41, 48, 49], which might lead to insufficient clinical activity or resistance of targeted therapies in gastric cancer. This evidence concerns the gene FGFR2 and gastric cancer.